Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany.
Canopy Growth Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$18.72|
|52 Week High||CA$18.40|
|52 Week Low||CA$71.60|
|1 Month Change||-11.53%|
|3 Month Change||-34.73%|
|1 Year Change||-13.21%|
|3 Year Change||-70.96%|
|5 Year Change||378.77%|
|Change since IPO||622.78%|
Recent News & Updates
|WEED||CA Pharmaceuticals||CA Market|
Return vs Industry: WEED underperformed the Canadian Pharmaceuticals industry which returned 29.2% over the past year.
Return vs Market: WEED underperformed the Canadian Market which returned 29% over the past year.
Stable Share Price: WEED is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: WEED's weekly volatility (6%) has been stable over the past year.
About the Company
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company’s products include dried cannabis flowers, oils and concentrates, and softgel capsules.
Canopy Growth Fundamentals Summary
|WEED fundamental statistics|
Is WEED overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|WEED income statement (TTM)|
|Cost of Revenue||CA$458.55m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-3.30|
|Net Profit Margin||-217.31%|
How did WEED perform over the long term?See historical performance and comparison
Is Canopy Growth undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: WEED (CA$18.72) is trading below our estimate of fair value (CA$51.45)
Significantly Below Fair Value: WEED is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: WEED is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.
PE vs Market: WEED is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate WEED's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: WEED is good value based on its PB Ratio (1.8x) compared to the CA Pharmaceuticals industry average (2.6x).
How is Canopy Growth forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: WEED is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: WEED is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: WEED's is expected to become profitable in the next 3 years.
Revenue vs Market: WEED's revenue (29% per year) is forecast to grow faster than the Canadian market (6.1% per year).
High Growth Revenue: WEED's revenue (29% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: WEED is forecast to be unprofitable in 3 years.
How has Canopy Growth performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WEED is currently unprofitable.
Growing Profit Margin: WEED is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: WEED is unprofitable, and losses have increased over the past 5 years at a rate of 63.8% per year.
Accelerating Growth: Unable to compare WEED's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WEED is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (115.1%).
Return on Equity
High ROE: WEED has a negative Return on Equity (-26.93%), as it is currently unprofitable.
How is Canopy Growth's financial position?
Financial Position Analysis
Short Term Liabilities: WEED's short term assets (CA$2.7B) exceed its short term liabilities (CA$256.1M).
Long Term Liabilities: WEED's short term assets (CA$2.7B) exceed its long term liabilities (CA$2.4B).
Debt to Equity History and Analysis
Debt Level: WEED's debt to equity ratio (36.5%) is considered satisfactory.
Reducing Debt: WEED's debt to equity ratio has increased from 3.1% to 36.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: WEED has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if WEED has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Canopy Growth current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate WEED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate WEED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if WEED's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WEED's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of WEED's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Klein (57 yo)
Mr. David Eric Klein has been the Chief Executive Officer at Canopy Growth Corporation since January 14, 2020 and has been its Director since November 1, 2018. Mr. Klein served as Chairman of the Board at...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD2.76M) is about average for companies of similar size in the Canadian market ($USD3.56M).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
Experienced Management: WEED's management team is considered experienced (2.2 years average tenure).
Experienced Board: WEED's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.9%.
Canopy Growth Corporation's employee growth, exchange listings and data sources
- Name: Canopy Growth Corporation
- Ticker: WEED
- Exchange: TSX
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$7.362b
- Shares outstanding: 393.29m
- Website: https://www.canopygrowth.com
Number of Employees
- Canopy Growth Corporation
- 1 Hershey Drive
- Smiths Falls
- K7A 0A8
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 22:13|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.